Thomas Duhen: IL-12 drives the expression of NKG2A on human tumor-reactive CD8 T cells
Thomas Duhen, Assistant Member at Earle A. Chiles Research Institute, shared an article on LinkedIn:
“Our paper showing that IL-12 drives the expression of NKG2A on human tumor-reactive CD8 T cells has just been published by Nature Communications.
This work led by Dr Fesneau highlights that IL-12, while driving CD8 T cells to differentiate into cytotoxic T cells, can also lead to the up-regulation of immunoregulatory molecules such as NKG2A and CD39.”
IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells.
Authors: Olivier Fesneau, et al.
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, reshared the post on LinkedIn, adding:
“Drs. Thomas Duhen and Olivier Fesneau, PhD thanks for allowing us to collaborate with you on this important project. Unravelling mechanisms that play a role in tumor escape will ultimately lead to novel combination immunotherapies and improved outcomes for patients with cancer.
This work is an important contribution to that goal.”
Bernard A. Fox is the Co-Founder, President, and CEO of UbiVac. He is an Adjunct Professor in the Department of Molecular Microbiology and Immunology, at the Knight Cancer Institute. He is also a Member of Board of Directors at Oregon Bioscience Association.In 2012, Dr. Fox received the Harder Family Endowed Chair for Cancer Research in recognition of his efforts in translational cancer therapy.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023